Efficacy and safety of reduced‐dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real‐world observational study
Cancer Medicine · 2023-09 · 12 (18) · 18679-18690
DOI: 10.1002/cam4.6478 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 07.09.2023. Verfasst von Ganlu Ouyang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Immunotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Recently, chemotherapy plus immunotherapy has achieved remarkable efficacy in lung squamous cell carcinoma (LUSC). However, some patients, especially frail people, cannot tolerate full‐dose chemotherapy in the real world. To reduce toxicity, appropriate dose reduction in chemotherapy is necessary. Therefore, this study aimed to demonstrate the efficacy and safety of reduced‐dose chemotherapy plus immunotherapy in LUSC patients in the real world.
Methods
A real‐world observational study was conducted concerning patients who received chemotherapy plus immunotherapy in our situation. The primary endpoints were objective response rate (ORR) and disease control rate (DCR), and the secondary endpoints were progression‐free survival (PFS), overall survival (OS), and toxicity.
Results
Between December 2018 and January 2022, 110 patients were enrolled, of whom 54 patients were chemotherapy reduced‐dose group and 56 patients were chemotherapy standard‐dose group. The ORR in the reduced‐dose group is similar to standard‐dose group (85.19% vs. 71.43%, p = 0.082). Similar DCR were observed (100% vs. 94.64%, p = 0.086). Median PFS was 12 months in the reduced‐dose group and standard‐dose group, respectively. Median OS was 15 months and 16 months in the reduced‐dose group and standard‐dose group, respectively. We reported a lower incidence of grade 3–4 toxicity in the reduced‐dose group compared with standard‐dose group (27.78% vs. 42.86%, p = 0.100). The major toxic reactions were better alleviated in the reduced‐dose group than in the standard‐dose group, especially in the thrombocytopenia ( p = 0.044), peripheral nerve damage ( p = 0.001), gastrointestinal reactions ( p < 0.0001), and fatigue ( p = 0.001).
Conclusions
The modified regimen with attenuated doses of chemotherapy in combination with immunotherapy was effective and well tolerated in patients with LUSC. The efficacy of this modified regimen is similar to that of the full‐dose regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Ganlu Ouyang
Förderung
- The National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Ouyang, G., Liu, Y., Liu, J., Huang, L., Luo, F., & Li, L. (2023). Efficacy and safety of reduced‐dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real‐world observational study. Cancer Medicine, 12(18), 18679-18690. https://doi.org/10.1002/cam4.6478
Vancouver
Ouyang G, Liu Y, Liu J, Huang L, Luo F, Li L. Efficacy and safety of reduced‐dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real‐world observational study. Cancer Medicine. 2023;12(18):18679-18690. doi:10.1002/cam4.6478
BibTeX
@article{Ouyang2023,
author = {Ouyang, Ganlu and Liu, Yanyang and Liu, Jiewei and Huang, Lin and Luo, Feng and Li, Lu},
title = {Efficacy and safety of reduced‐dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real‐world observational study},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {18},
pages = {18679--18690},
doi = {10.1002/cam4.6478}
}
EUVIMED